ADXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Advaxis's average Accounts Receivable for the three months ended in Mar. 2023 was $0.00 Mil. Advaxis's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Hence, Advaxis's Days Sales Outstanding for the three months ended in Mar. 2023 was 91.25.
The historical rank and industry rank for Advaxis's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Advaxis's highest Days Sales Outstanding was 100.17. The lowest was 5.75. And the median was 64.63.
Advaxis's Days Sales Outstanding increased from Jan. 2022 (0.00) to Mar. 2023 (91.25).
The historical data trend for Advaxis's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Advaxis's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Advaxis's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Advaxis's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Advaxis's Days Sales Outstanding for the fiscal year that ended in Oct. 2022 is calculated as
Days Sales Outstanding (A: Oct. 2022 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Oct. 2021 ) | + | Accounts Receivable (A: Oct. 2022 )) | / | count ) | / | Revenue (A: Oct. 2022 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0.25 | * | 365 |
= | 0 | / | 0.25 | * | 365 | ||||
= | 0.00 |
Advaxis's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:
Days Sales Outstanding (Q: Mar. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Oct. 2022 ) | + | Accounts Receivable (A: Mar. 2023 )) | / | count ) | / | Revenue (A: Mar. 2023 ) | * | Days in Period |
= | ( (0 | + | 0.004) | / | 1 ) | / | 0.004 | * | 365 / 4 |
= | 0.004 | / | 0.004 | * | 365 / 4 | ||||
= | 91.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advaxis (OTCPK:ADXS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Advaxis's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Roy Golan | officer: Chief Financial Officer | 24 GOLDA MEIR ST., HOLON L3 5840425 |
Yuval Cabilly | director | C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348 |
Pini Orbach | director | C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802 |
Bridget A Martell | director | C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
Israel Biotech Fund Ii, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Israel Biotech Fund Gp Partners Ii, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Murray A Goldberg | director | 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Vered Bisker-leib | director | C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142 |
Israel Biotech Fund I, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Amoon Growth Fund Limited Partnership | 10 percent owner | 34 YERUSHALAYIM RD., RAANANA L3 4350110 |
Israel Biotech Fund Gp Partners, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Yair Chaim Schindel | 10 percent owner | YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110 |
I.b.f. Management Ltd. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Igor Gitelman | officer: Chief Accounting Officer | 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070 |
From GuruFocus
By sperokesalga 06-05-2023
By GuruFocusNews 06-05-2022
By GuruFocusNews 06-29-2022
By GuruFocusNews 07-08-2022
By GlobeNewswire 05-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.